sBLA and NDA Submitted to FDA for Amivantamab and Lazertinib in EGFR-Mutant NSCLC

A supplemental biologics license application and new drug application seeking the approval of amivantamab plus lazertinib as frontline therapy for the treatment of patients with locally advanced or metastatic NSCLC with EGFR mutations have been submitted to the FDA.

Related Keywords

Kiran Patel ,Clinical Development ,Johnson ,Solid Tumors ,Johnson Innovative Medicine ,Fda ,Amivantamab ,Rybrevant ,Lazertinib ,Nsclc ,Phase 3 Mariposa Trial Nct04487080 ,